预约演示

Pfizer takes scalpel to early-phase pipeline, slicing off RSV, eczema, sickle cell and cancer programs

2023-08-01

临床1期疫苗并购临床2期引进/卖出

Pfizer thinned its sickle cell pipeline 10 months after its buyout of Global Blood Therapeutics.

Pfizer is ringing the changes as it exits the second quarter, tossing Global Blood Therapeuticsal vaccine candidate and a handful of phase 1 assets including a respiratory syncytial virus (RSV) prospect it picked up in last year’s ReViral takeover.

Pfizerarterly pipeline update (PDF) features the removal of two phase 2 assets, including the previously disclosed defenestration of its oral obesity and diabetes candidate lotiglipron over safety concerns. The other phase 2 candidReViralget the ax in the update is PF-06842433, a vaccine that was in development for the prevention of invasive and noninvasive pneumococcal infections in infants and children.

Pfizer ran (PDF) a phase 1/2 clinical trial of the seven-valent pneumococcal conjugate vaccine from 2018 to 2020. The vaccine candidate was deobesityto codiabetes the pneumolotiglipronrage provided by Prevnar 13, but, with Prevnar 20 now approved, Pfizer has moved oPF-06842433program.invasive and noninvasive pneumococcal infections

Pfizerdate also covers the discontinuation of six phase 1 assets, including PF-07923567. The N-protein inhibitor, also known as RV-299, is one of the RSV candidates that Pfizer added to its pipeline in a deal to buy ReViral for $436 million upfrontPfizeryear. Work on the most advanced program included in the deal, sisunatovir, continues, but Pfizer has decided it can do without PF-07923567.

Pfizer is also jettisoning a pair of atopic dermatitis programs and another PF-07923567id tumN-protein inhibitorc dermatitis, thRV-299Pharma followed up the discontinuatiPfizerone topical “soft” JAK inhibitor last yeReViralxing a similar molecule that it was studying in the same phase 1 trial. Alongside that, it hasisunatovir242813, a CD1a inPfizerr, after wrapping up a phase 1 PF-07923567althy volunteers and atopic dermatitis patients.

Pfizerlid tumor discontinuations fallatopic dermatitis inhibitor PF-07265807 and thesolid tumorator PF-0720atopic dermatitisired the AXL/MERTK inhibitor in the Array BioPharma buyout, but evidencJAK inhibitor JAKhe mechanism lowers the immune activation threshold and boosts anti-tumor immunity has failed to yield a clinical candidate PF-07242813er tCD1as warrants further development.atopic dermatitis

Finasolid tumor has thinned its sickle cell pipeline 10 months afPF-07265807out of GlIL15 Blood TherPF-07209960siPfizer it as a force in the indication. The disArray BioPharmafects PF-07209326, an anti-E-selectin inhibitor that was in development at Pfizer prior to tumorlobal Blood takeover. The confirmation follows the news last week that Pfizer is walking away from a sickle cell disease licensing deal with Syros Pharmaceuticals that it inherited from its takeover of Global Blood.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构